| A | B | C | D | E | F | G | H | I | J | K | L | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ||||||||||||
| 2 | Brand | Generic | Indication | MOA | Economics | Approved | IP | Price | 131 | |||
| 3 | Comirnaty | COVID-19 | mRNA vaccine | PFE | MRNA IP challenge | Shares | 242.685401 | Q222 | ||||
| 4 | MC | 31791.787531 | ||||||||||
| 5 | Omicron BA.1 bivalent | Cash EUR | 13481 | Q322 | ||||||||
| 6 | BA.4/5 | Debt EUR | 967 | Q322 | ||||||||
| 7 | BNT116 | EV | 19277.787531 | |||||||||
| 8 | BNT211 | CLDN6 CART | ||||||||||
| 9 | BNT163 | HSV-2 vaccine | Vaccine | Prof. Ugur Sahin | ||||||||
| 10 | BNT142 | |||||||||||
| 11 | ||||||||||||
| 12 | 8/8/22: Q222 results. Reiterates 13B-17B EUR COVID-19 revenue. | |||||||||||
| 13 | 2008: Founded |